Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385356925> ?p ?o ?g. }
Showing items 1 to 71 of
71
with 100 items per page.
- W4385356925 abstract "Background: the first generation of biotechnology drugs is reaching, or has already reached, the patent expiry and a large number of biosimilars is entering the Italian pharmaceutical market. The objective of the analysis was to evaluate the economic impacts of biosimilars on the national health expenditure in Italy between 2014 and 2020. Methods: Based on the information deriving from consumption per standard unit and equivalent patients, it was estimated monthly expenditure for some of the biological drugs currently available in Italy that have had or will have a patent expiry within the analysis period (infliximab, etanercept, adalimumab, insulin glargine, trastuzumab, rituximab, bevacizumab and insulin aspart). Pharmaceutical expenditure was calculated on hospital sales prices net of transparent discounts required by law and visible from the AIFA database. Three alternative scenarios have been developed based on the perceptions of a board of clinical experts, pharmacologists and pharmacoeconomists involved in the study. The experts involved analyzed the estimates of treated patients between 2014 and 2017 and reports their hypothetical biosimilar penetration during the period 2018-2020. The results were represented as the difference between the estimated expenditure in the absence of biosimilars and the estimated expenditure in the presence of biosimilars with the real or hypothetical biosimilar penetration. Results: considering the standard units dispensed for each year, the economic model estimate an annual expenditure in 2014 equal to € 1.47 billion for the molecules considered in the analysis. These estimates rise to € 1.54, € 1.50 billion and € 1.51 billion during 2015, 2016 and 2017 in the scenario without biosimilar introduction. Biosimilar introduction generates cost savings between € 3.8 million in 2015 and € 32.9 million in 2017 if compared with the scenario without. Assuming an increasing biosimilar penetration between 2018 and 2020, scenario analysis estimates a cumulative cost reduction equal to € 597 million. Conclusions: Overall, biosimilar penetration generates important cost reduction that could be re-invested in the National Health Sistem." @default.
- W4385356925 created "2023-07-29" @default.
- W4385356925 creator A5000892248 @default.
- W4385356925 creator A5003585738 @default.
- W4385356925 creator A5009764670 @default.
- W4385356925 creator A5018441101 @default.
- W4385356925 creator A5031340334 @default.
- W4385356925 creator A5038529742 @default.
- W4385356925 creator A5043265559 @default.
- W4385356925 creator A5046225608 @default.
- W4385356925 creator A5048225825 @default.
- W4385356925 creator A5054065835 @default.
- W4385356925 creator A5071033007 @default.
- W4385356925 creator A5074903334 @default.
- W4385356925 creator A5075368922 @default.
- W4385356925 creator A5077541772 @default.
- W4385356925 creator A5087114501 @default.
- W4385356925 creator A5088217343 @default.
- W4385356925 date "2019-08-16" @default.
- W4385356925 modified "2023-09-30" @default.
- W4385356925 title "The economic impact of biosimilars in Italy: a scenario analysis" @default.
- W4385356925 doi "https://doi.org/10.33393/grhta.2019.457" @default.
- W4385356925 hasPublicationYear "2019" @default.
- W4385356925 type Work @default.
- W4385356925 citedByCount "0" @default.
- W4385356925 crossrefType "journal-article" @default.
- W4385356925 hasAuthorship W4385356925A5000892248 @default.
- W4385356925 hasAuthorship W4385356925A5003585738 @default.
- W4385356925 hasAuthorship W4385356925A5009764670 @default.
- W4385356925 hasAuthorship W4385356925A5018441101 @default.
- W4385356925 hasAuthorship W4385356925A5031340334 @default.
- W4385356925 hasAuthorship W4385356925A5038529742 @default.
- W4385356925 hasAuthorship W4385356925A5043265559 @default.
- W4385356925 hasAuthorship W4385356925A5046225608 @default.
- W4385356925 hasAuthorship W4385356925A5048225825 @default.
- W4385356925 hasAuthorship W4385356925A5054065835 @default.
- W4385356925 hasAuthorship W4385356925A5071033007 @default.
- W4385356925 hasAuthorship W4385356925A5074903334 @default.
- W4385356925 hasAuthorship W4385356925A5075368922 @default.
- W4385356925 hasAuthorship W4385356925A5077541772 @default.
- W4385356925 hasAuthorship W4385356925A5087114501 @default.
- W4385356925 hasAuthorship W4385356925A5088217343 @default.
- W4385356925 hasBestOaLocation W43853569251 @default.
- W4385356925 hasConcept C126322002 @default.
- W4385356925 hasConcept C2777138892 @default.
- W4385356925 hasConcept C2779134260 @default.
- W4385356925 hasConcept C59491497 @default.
- W4385356925 hasConcept C71924100 @default.
- W4385356925 hasConceptScore W4385356925C126322002 @default.
- W4385356925 hasConceptScore W4385356925C2777138892 @default.
- W4385356925 hasConceptScore W4385356925C2779134260 @default.
- W4385356925 hasConceptScore W4385356925C59491497 @default.
- W4385356925 hasConceptScore W4385356925C71924100 @default.
- W4385356925 hasIssue "1" @default.
- W4385356925 hasLocation W43853569251 @default.
- W4385356925 hasOpenAccess W4385356925 @default.
- W4385356925 hasPrimaryLocation W43853569251 @default.
- W4385356925 hasRelatedWork W1981336058 @default.
- W4385356925 hasRelatedWork W2328722664 @default.
- W4385356925 hasRelatedWork W2586347026 @default.
- W4385356925 hasRelatedWork W2774189845 @default.
- W4385356925 hasRelatedWork W2799488547 @default.
- W4385356925 hasRelatedWork W2944483536 @default.
- W4385356925 hasRelatedWork W3093730414 @default.
- W4385356925 hasRelatedWork W4231459691 @default.
- W4385356925 hasRelatedWork W4253615316 @default.
- W4385356925 hasRelatedWork W4379521643 @default.
- W4385356925 hasVolume "6" @default.
- W4385356925 isParatext "false" @default.
- W4385356925 isRetracted "false" @default.
- W4385356925 workType "article" @default.